Breaking good: the inexorable rise of BTK inhibitors in the treatment of chronic lymphocytic leukaemia.
about
Ibrutinib in Waldenström macroglobulinemia: latest evidence and clinical experienceA critical appraisal of ibrutinib in the treatment of mantle cell lymphoma and chronic lymphocytic leukemiaA phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignanciesHumoral immune responses toward tumor-derived antigens in previously untreated patients with chronic lymphocytic leukemia.Ibrutinib for mantle cell lymphoma.Call for Action: Invasive Fungal Infections Associated With Ibrutinib and Other Small Molecule Kinase Inhibitors Targeting Immune Signaling Pathways.
P2860
Breaking good: the inexorable rise of BTK inhibitors in the treatment of chronic lymphocytic leukaemia.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Breaking good: the inexorable ...... chronic lymphocytic leukaemia.
@en
type
label
Breaking good: the inexorable ...... chronic lymphocytic leukaemia.
@en
prefLabel
Breaking good: the inexorable ...... chronic lymphocytic leukaemia.
@en
P2860
P356
P1476
Breaking good: the inexorable ...... chronic lymphocytic leukaemia
@en
P2093
Claire V Hutchinson
P2860
P356
10.1111/BJH.12895
P407
P50
P577
2014-04-18T00:00:00Z